Fig. 5
From: Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
DNA methylation and gene expression of HSPB2. a The single CpG methylation of HSPB2 among nontumor brains and GBMs or gliomas of each grade. b gene expression patterns of HSPB2 among nontumor brains and GBMs or gliomas of each grade. c Correlations of the single CpG methylation and gene expression of HSPB2 in each cohort. d Representative HSPB2 IHC staining and pyrosequencing results (left) and the correlation of IHC staining scores and pyrosequencing data (right) in FFPE samples of IDHR132H wild-type GBMs. e HSPB2 single CpG pyrosequencing data in each GBM cell line. f, g Real-time PCR and western blot results of HSPB2 expressions in different GBM cell lines with either hypermethylated CpG (e.g., U251 and U373) or hypomethylated CpG (e.g., U87) after demethylation treatment with 5-Aza-dC at different doses (e.g., control, 5 nM, 10 nM). GBM glioblastoma, G-CIMP glioma-CpGs island methylator phenotype, FFPE formalin-fixed paraffin-embedded, wt wild type